Vigafyde is a drug owned by Pyros Pharmaceuticals Inc. It is protected by 1 US drug patent filed in 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 16, 2039. Details of Vigafyde's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12016857 | Stable liquid vigabatrin pharmaceutical composition for oral dosage |
Aug, 2039
(14 years from now) | Active |
US patents provide insights into the exclusivity only within the United States, but Vigafyde is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Vigafyde's family patents as well as insights into ongoing legal events on those patents.
Vigafyde's Family Patents
Try Our Curated Drug Screens
Generic Launch
Generic Release Date:
Vigafyde's generic launch date based on the expiry of its last outstanding patent is estimated to be Aug 16, 2039 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Vigafyde Generics:
Vigabatrin is the generic name for the brand Vigafyde. 20 different companies have already filed for the generic of Vigafyde, with Aurobindo Pharma Ltd having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Vigafyde's generic
About Vigafyde
Vigafyde is a drug owned by Pyros Pharmaceuticals Inc. Vigafyde uses Vigabatrin as an active ingredient. Vigafyde was launched by Pyros Pharms in 2024.
Approval Date:
Vigafyde was approved by FDA for market use on 17 June, 2024.
Active Ingredient:
Vigafyde uses Vigabatrin as the active ingredient. Check out other Drugs and Companies using Vigabatrin ingredient
Dosage:
Vigafyde is available in solution form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 100MG/ML | SOLUTION | Prescription | ORAL |